Avertto Medical

Company Overview

Snapshot

Founded in October 2019, Avertto Medical operates with 1–10 employees and has raised a total of $3.7 million across two funding rounds. The company focuses on developing AI-powered solutions for early stroke detection and prevention. In June 2023, Avertto Medical won the Asper Prize from Hebrew University’s ASPER-HUJI Innovate, recognizing its innovative stroke-preventing technology.

Business overview

Avertto Medical addresses the critical need for early stroke detection and prevention with its AI-powered neck device. This solution utilizes neck sensors to monitor, detect changes, and alert responsive care, aiming to enable treatment within the 'golden hour' before neuronal injury occurs. The company targets the health tech and life sciences sectors, specifically within digital healthcare and medical devices, serving healthcare providers in markets such as the United States and Europe.

Strategic signal

In June 2023, Avertto Medical secured the Asper Prize from Hebrew University’s ASPER-HUJI Innovate, winning NIS 100,000 for its stroke-preventing technology. This recognition validates the company's innovative approach to real-time stroke detection and prevention through blood flow monitoring, signaling strong potential for timely treatment and alignment with global health objectives.

Company Intelligence Q&A

What is Avertto Medical's primary focus?

Avertto Medical focuses on addressing the critical gap in stroke prevention and care by developing an AI-powered neck device that uses sensors for monitoring, detecting changes, and alerting responsive care to prevent impending strokes.

When was Avertto Medical founded?

Avertto Medical was founded in October 2019.

What was a significant achievement for Avertto Medical in June 2023?

In June 2023, Avertto Medical won the Asper Prize from Hebrew University’s ASPER-HUJI Innovate, receiving NIS 100,000 for its stroke-preventing technology after competing with 44 other startups.

What is Avertto Medical's business model for revenue generation?

Avertto Medical's business model in the US leverages ICU disposable reimbursements, strategically setting a sale price at $847 per patient for up to one week of use, aiming for quick market infiltration without needing to develop a new reimbursement rate.

What clinical studies has Avertto Medical completed?

Avertto Medical has completed POC studies with 70 participants across Rabin, Galilee Medical Center in Israel, and VDH in Barcelona, and a successful space mission astronaut study with 4 participants during Axiom1.